Alloy Therapeutics, Inc. announced a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited to develop Takeda’s proprietary iPSC derived CAR-T cell platform and iPSC-derived CAR-NK platform.
[Alloy Therapeutics, Inc.]
